

添付書類 3

添付3-1 非採用文献リスト(A) 英文50+和文11=61文献

No	Author	Title	Journal	Volu mes	Issu e	Page s	Year
A1	Homma Y, Akaza H, Okada K, Yokoyama M, Usami M, Hirao Y, Tsushima T, Sakamoto A, Ohashi Y, Aso Y; Prostate Cancer Study Group.	Endocrine therapy with or without radical prostatectomy for T1b-T3N0M0 prostate cancer.	Int J Urol	11	4	218-24	2004
A2	Namiki S, Saito S, Tochigi T, Kuwahara M, Ioritani N, Yoshimura K, Terai A, Koinuma N, Arai Y.	Impact of hormonal therapy prior to radical prostatectomy on the recovery of quality of life.	Int J Urol	12	2	173-81	2005
A3	Okihara K, Nakanishi H, Nakamura T, Mizutani Y, Kawauchi A, Miki T.	Clinical characteristics of prostate cancer in Japanese men in the eras before and after serum prostate-specific antigen testing.	Int J Urol	12	7	662-7	2005
A4	北村浩二, 増田健人, 中村晃和, 沖原宏治, 浮村理, 河内明宏, 三木恒治.	前立腺全摘除術を施行した検診発見前立腺がんの治療成績.	日本がん検診・診断学会誌	11	2	94-7	2004
A5	山本巧, 伊藤一人, 大井勝, 武智浩之, 坂西理恵, 黒川公平, 鈴木和浩, 山中英壽.	前立腺特異抗原(PSA)による前立腺がん検診と精度管理.	日本がん検診・診断学会誌	11	2	1937-9	2004
A6	平野恭弘, 古瀬洋, 佐藤崇, 鈴木泰介, 福田健, 北川元昭, 阿曾佳郎.	藤枝市における前立腺癌検診8年間の結果からみた検診間隔の検討.	日本腎泌尿器疾患予防医学研究会誌	12	1	38-40	2004
A7	古賀寛史, 山口秋人, 宮崎良春, 辻祐治, 太田康弘, 内藤誠二.	前立腺癌PSA単独検診の問題点 -2次検診PSA基準値未満例について.-	日本腎泌尿器疾患予防医学研究会誌	12	1	44-6	2004
A8	北村浩二, 増田健人, 沖原宏治, 浮村理, 河内明宏, 三木恒治.	検診で発見された前立腺癌のホルモン治療成績.	日本腎泌尿器疾患予防医学研究会誌	12	1	1961-2	2004
A9	内藤 誠二, 小藤 秀嗣, 熊澤 浄一, 尾本 徹男, 伊東 健治, 畑地 康助, 清水 保夫, 横山 譲二, 永芳 弘之, 鷺山 和幸, 長谷川 淑博, 森田 一喜朗, 太田 康弘, 箕田 薫, 本村 精二.	福岡県におけるドック前立腺検診の現状と問題点.	日本泌尿器科学会雑誌	84	7	1227-35	1993
A10	加藤司顯, 多武保光宏, 吉松正, 太田雅也, 金城真実, 野田治久, 渡辺和吉, 宮田晃臣, 村田明弘, 三浦一郎, 米田龍生, 吉井将人, 桶川隆嗣, 小島美保, 佐山孝, 奴田原紀久雄, 東原英二.	前立腺癌の早期診断における検診の意義.	日本泌尿器科学会雑誌	92	1	23-9	2001
A11	金山博臣, 香川征, 宇都宮正登, 川島周, 武久一郎, 炭谷晴雄, 横関秀明.	徳島市前立腺がん検診について(第一報):平成13年度初年度の結果に対する解析.	日本泌尿器科学会雑誌	95	3	596-603	2004
A12	Madalinska JB, Essink-Bot ML, de Koning HJ, Kirkels WJ, van der Maas PJ, Schröder FH.	Health-related quality of life in patients with screen-detected versus clinically diagnosed prostate cancer preceding primary treatment.	Prostate	46	2	87-97	2001
A13	Hugosson J, Aus G, Lilja H, Lodding P, Pihl C.G, Pileblad E.	Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.	J Urol	169	5	1720-3	2003
A14	Hugosson J, Aus G, Lilja H, Lodding P, Pihl C-G.	Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.	Cancer	100	7	1397-405	2004

A15	Roobol MJ, van der Cruijssen IW, Schröder FH.	No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/ml or greater (ERSPC, Rotterdam).	Urol	63	5	892-7	2004
A16	Martin E, Lujan M, Sanchez E, Herrero A, Paez A, Berenguer A.	Final results of a screening campaign for prostate cancer.	Eur Urol	35	1	26-31	1999
A17	Hoedemaeker RF, Kranse R, Rietbergen JBW, Boeken Kruger AE, Schröder FH, Van der Kwast TH.	Evaluation of prostate needle biopsies in a population-based screening study: the impact of borderline lesions.	Cancer	85	1	145-52	1999
A18	Crawford ED, Pinsky PF, Chia D, Kramer BS, Fagerstrom RM, Andriole G, Reding D, Gelmann EP, Levin DL, Gohagan JK	Prostate specific antigen changes as related to the initial prostate specific antigen: data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.	J Urol	175	4	1286-90	2006
A19	Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK.	Prostate cancer screening: what we know and what we need to know.	Ann Intern Med	119	9	914-23	1993
A20	Draisma G, De Koning HJ.	MISCAN: estimating lead-time and over-detection by simulation.	BJU Int	92	Supp 1 2	106-11	2003
A21	Hugosson J, Aus G, Bergdahl S, Fernlund P, Frosing R, Lodding P, Pihl CG, Lilja H.	Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden.	BJU Int	92	Supp 1 2	39-43	2003
A22	Postma R, Roobol M, Schroder FH, van der Kwast TH.	Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years.	Cancer	100	5	968-75	2004
A23	Ito K, Yamamoto T, Ohi M, Takechi H, Kurokawa K, Suzuki K, Yamanaka H.	Cumulative probability of PSA increase above 4.0 NG/ML in population-based screening for prostate cancer.	Int J Cancer	109	3	455-60	2004
A24	Steiner H, Moser P, Hager M, Berger AP, Klocker H, Spranger R, Rogatsch H, Bartsch G, Horninger W.	Clinical and pathologic features of prostate cancer detected after repeat false-negative biopsy in a screening population.	Prostate	58	3	277-82	2004
A25	Nicholson PW, Harland SJ.	Survival prospects after screen-detection of prostate cancer.	BJU Int	90	7	686-93	2002
A26	Lewis JS Jr, Vollmer RT, Humphrey PA.	Carcinoma extent in prostate needle biopsy tissue in the prediction of whole gland tumor volume in a screening population.	Am J Clin Pathol	118	3	442-50	2002
A27	Valeri A, Cormier L, Moineau MP, Cancel-Tassin G, Azzouzi R, Doucet L, Baschet F, Cussenot I, L'Her J, Berthon P, Mangin P, Cussenot O, Morin JF, Fournier G.	Targeted screening for prostate cancer in high risk families: early onset is a significant risk factor for disease in first degree relatives.	J Urol	168	2	483-7	2002
A28	Uozumi J, Tokuda Y, Fujiyama C, Takagi N, Meiri H, Kuratomi K, Nakamura K, Ichigi Y, Yoshinaga H, Kinoshita N, Masaki Z.	Annual PSA tests are not necessary for men with a PSA level below 2 ng/mL: findings of the Imari prostate cancer screening program.	Int J Urol	9	6	334-9	2002
A29	Finne P, Auvinen A, Aro J, Juusela H, Maattanen L, Rannikko S, Hakama M, Tammela TL, Stenman UH.	Estimation of prostate cancer risk on the basis of total and free prostate-specific antigen, prostate volume and digital rectal examination.	Eur Urol	41	6	619-26; discussion 626-	2002
A30	Makinen T, Tammela TL, Stenman UH, Maattanen L, Rannikko S, Aro J, Juusela H, Hakama M, Auvinen A.	Family history and prostate cancer screening with prostate-specific antigen.	J Clin Oncol	20	11	2658-63	2002

A31	Hoedemaeker RF, van der Kwast TH, Boer R, de Koning HJ, Roobol M, Vis AN, Schroder FH.	Pathologic features of prostate cancer found at population-based screening with a four-year interval.	J Natl Cancer Inst	93	15	1153-8	2001
A32	Schroder FH, Roobol-Bouts M, Vis AN, van der Kwast T, Kranse R.	Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.	Urology	57	1	83-90	2001
A33	Roberts RO, Bergstralh EJ, Lieber MM, Jacobsen SJ.	Digital rectal examination and prostate-specific antigen abnormalities at the time of prostate biopsy and biopsy outcomes, 1980 to 1997.	Urology	56	5	817-22	2000
A34	Ross KS, Carter HB, Pearson JD, Guess HA.	Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection.	JAMA	284	11	1399-405	2000
A35	Uchida K, Takeshima H, Akaza H, Ono Y.	Screening for prostate cancer using prostate-specific antigen alone as a first-line checkup parameter: results of the health checkup system.	Jpn J Clin Oncol	30	2	95-100	2000
A36	Smith DS, Carvalhal GF, Schneider K, Krygiel J, Yan Y, Catalona WJ.	Quality-of-life outcomes for men with prostate carcinoma detected by screening.	Cancer	88	6	1454-63	2000
A37	Horninger W, Reissigl A, Rogatsch H, Volgger H, Studen M, Klocker H, Bartsch G.	Prostate cancer screening in Tyrol, Austria: experience and results.	Eur Urol	35	5-6	523-38	1999
A38	Zappa M, Ciatto S, Bonardi R, Mazzotta A.	Overdiagnosis of prostate carcinoma by screening: an estimate based on the results of the Florence Screening Pilot Study.	Ann Oncol	9	12	1297-300	1998
A39	Di Matteo L, Di Matteo R.	Does testing for prostate-specific antigen contribute to declining prostate cancer mortality? Estimating the broader economic influences on aggregate prostate cancer mortality rates.	Eur J Health Econ	6	4	298-308	2005
A40	Bangma CH, Kranse R, Blijenberg BG, Schroder FH.	Free and total prostate-specific antigen in a screened population.	Br J Urol	79	5	756-62	1997
A41	Helgesen F, Holmberg L, Johansson JE, Bergstrom R, Adami HO.	Trends in prostate cancer survival in Sweden, 1960 through 1988: evidence of increasing diagnosis of nonlethal tumors.	J Natl Cancer Inst	88	17	1216-21	1996
A42	Parkes C, Wald NJ, Murphy P, George L, Watt HC, Kirby R, Knekt P, Helzlsouer KJ, Tuomilehto J.	Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer.	BMJ	311	7016	1340-3	1995
A43	Reissigl A, Pointner J, Horninger W, Ennemoser O, Strasser H, Klocker H, Bartsch G.	Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: results of a large screening study.	Urology	46	5	662-5	1995
A44	Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB.	Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.	JAMA	274	15	1214-20	1995
A45	Ciatto S, Bonardi R, Mazzotta A, Lombardi C, Santoni R, Cardini S, Zappa M.	Comparing two modalities of screening for prostate cancer: digital rectal examination + transrectal ultrasonography vs. prostate-specific antigen.	Tumori	81	4	225-9	1995
A46	Gustafsson O, Theorell T, Norming U, Perski A, Ohstrom M, Nyman CR.	Psychological reactions in men screened for prostate cancer.	Br J Urol	75	5	631-6	1995

A47	Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, MacFarlane MT, Southwick PC.	Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves.	J Urol	152	6 Pt 1	2037-42	1994
A48	Van der Kwast TH, Postma R, Hoedemaeker RF, van Leenders GJ, Schroder FH.	Features of prostate cancers detected during a prevalence screening round. The Rotterdam experience.	Can J Urol	12	Supp 1 2	16-20	2005
A49	Mettlin C, Murphy GP, Lee F, Littrup PJ, Chesley A, Babaian R, Badalament R, Kane RA, Mostofi FK.	Characteristics of prostate cancer detected in the American Cancer Society-National Prostate Cancer Detection Project.	J Urol	152	5 Pt 2	1737-40	1994
A50	Bretton PR.	Prostate-specific antigen and digital rectal examination in screening for prostate cancer: a community-based study.	South Med J	87	7	720-3	1994
A51	Mettlin C, Murphy GP, Lee F, Littrup PJ, Chesley A, Babaian R, Badalament R, Kane RA, Mostofi FK.	Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project.	Cancer	72	5	1701-8	1993
A52	Kramer BS, Gohagan J, Prorok PC, Smart C.	A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers.	Cancer	71	Supp 1 2	589-93	1993
A53	Gerber GS, Thompson IM, Thisted R, Chodak GW.	Disease-specific survival following routine prostate cancer screening by digital rectal examination.	JAMA	296	1	61-4	1993
A54	Kundu SD, Grubb RL, Roehl KA, Antenor JA, Han M, Catalona WJ.	Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2 ng/ml.	J Urol	173	4	1116-20	2005
A55	Coory MD, Baade PD.	Urban-rural differences in prostate cancer mortality, radical prostatectomy and prostate-specific antigen testing in Australia.	Med J Aust	182	3	112-5	2005
A56	Sennfalt K, Sandblom G, Carlsson P, Varenhorst E.	Costs and effects of prostate cancer screening in Sweden—a 15-year follow-up of a randomized trial.	Scand J Urol Nephrol	38	4	291-8	2004
A57	Davidov O, Zelen M.	Overdiagnosis in early detection programs.	Biostatistics	5	4	603-13	2004
A58	Gupta A, Roehrborn CG.	Verification and incorporation biases in studies assessing screening tests: prostate-specific antigen as an example.	Urology	64	1	106-11	2004
A59	Smith RP, Malkowicz SB, Whittington R, VanArsdalen K, Tochner Z, Wein AJ.	Identification of clinically significant prostate cancer by prostate-specific antigen screening.	Arch Intern Med	164	11	1227-30	2004
A60	Horninger W, Berger A, Pelzer A, Klocker H, Oberaigner W, Schonitzer D, Severi G, Robertson C, Boyle P, Bartsch G.	Screening for prostate cancer: updated experience from the Tyrol study.	Curr Urol Rep	5	3	220-5	2004
A61	Gavin A, McCarron P, Middleton RJ, Savage G, Catney D, O'Reilly D, Keane PF, Murray LJ.	Evidence of prostate cancer screening in a UK region.	BJU Int	93	6	730-4	2004

添付3-2 非採用文献リスト(B) 英文19+和文2=21文献

NO	Author	Title	Journal	Volu mes	Issu e	Page s	Year
B1	山本巧(群馬大学 泌尿器科), 伊藤一人, 大井勝, 久保田裕, 山中英壽	前立腺がん集団検診におけるPSA単独検診とPSA・直腸診併用検診の比較	日本がん検診・診断学会雑誌	8	2	63-6	2001
B2	中西弘之(京都府立医科大学 泌尿器科), 中尾昌宏, 野本剛史, 三木恒治, 中川修一, 北村浩二, 渡辺決	前立腺がん検診におけるカットオフ値としてのPSA年齢別基準値の検討	日本泌尿器科学会雑誌	90	11	853-8	1999
B3	Hoogendam A, Buntinx F, de Vet H C	The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis	Family Practice	16	6	621-6	1999
B4	Mäkinen T, Tammela TL, Hakama M, Stenman UH, Rannikko S, Aro J, Juusela H, Määtänen L, Auvinen A.	Tumor characteristics in a population-based prostate cancer screening trial with prostate-specific antigen	Clin Cancer Res	9	7	2435-9	2003
B5	Aus G, Becker C, Franzen S, Lilja H, Iodding P, Hugosson J	Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio	Eur Urol	45	2	160-5	2004
B6	De Vries SH, Postma R, Raaijmakers R, Roemeling S, Otto S, de Koning HJ, Schröder FH	Overall and Disease-Specific Survival of Patients with Screen-Detected Prostate Cancer in the European Randomized Study of Screening for Prostate Cancer, Section Rotterdam	Eur Urol	XXX			2006
B7	Rietbergen JBW, Hoedemaeker RF, Boeken Kruger AE, Kirkels WJ, Schröder FH.	The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancers in a population-based screening study.	J Urol	161	4	1192-8	1999
B8	Berenguer A, Lujan M, Paez A, Santonja C, Pascual T.	The Spanish contribution to the European Randomized Study of Screening for Prostate Cancer.	BJU Int	92	Suppl 1 2	33-8	2003
B9	Quaglia A, Vercelli M, Puppo A, Casella C, Artioli E, Crocetti E, Falcini F, Ramazzotti V, Tagliabue G; Prostate Working Group.	Prostate cancer in Italy before and during the 'PSA era': survival trend and prognostic determinants.	Eur J Cancer Prev	12	2	145-52	2003
B10	Ito K, Yamamoto T, Ohi M, Kurokawa K, Suzuki K, Yamanaka H.	Free/total PSA ratio is a powerful predictor of future prostate cancer morbidity in men with initial PSA levels of 4.1 to 10.0 ng/mL.	Urology	61	4	760-4	2003
B11	Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schonitzer D, Severi G, Robertson C, Boyle P; Tyrol Prostate Cancer Screening Group.	Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria.	Urology	58	3	417-24	2001
B12	加藤 司顕, 多武保 光宏, 吉松 正, 太田 雅也, 金城 真実, 野田 治久, 渡辺 和吉, 宮田 晃臣, 村田 明弘, 三浦 一郎, 米田 龍生, 吉井 将人, 桶川 隆嗣, 小島 美保, 佐山 孝, 奴田原 紀久雄, 東原 英二.	前立腺癌の早期診断における検診の意義.	日本泌尿器科学会雑誌	92	1	23-9	2001
B13	Beemsterboer PM, Kranse R, de Koning HJ, Habbema JD, Schroder FH.	Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam).	Int J Cancer	84	4	437-41	1999
B14	Meyer F, Moore L, Bairati I, Fradet Y.	Quebec prostate cancer mortality dropped in 1996.	Cancer Prev Control	2	4	163-6	1998

B15	Schroder FH, van der Maas P, Beemsterboer P, Kruger AB, Hoedemaeker R, Rietbergen J, Kranse R.	Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.	J Natl Cancer Inst	90	23	1817-23	1998
B16	Aus G, Damber JE, Khatami A, Lilja H, Stranne J, Hugosson J.	Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study.	Arch Intern Med	165	16	1857-61	2005
B17	Hoedemaeker RF, Rietbergen JB, Kranse R, van der Kwast TH, Schroder FH.	Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer.	World J Urol	15	6	339-45	1997
B18	Schroder FH, Raaijmakers R, Postma R, van der Kwast TH, Roobol MJ.	4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.	J Urol	174	2	489-94; discussion 493-4	2005
B19	Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF, Chia D, Kramer BS, Reding D, Church TR, Grubb RL, Izmirlian G, Ragard LR, Clapp JD, Prorok PC, Gohagan JK; PLCO Project Team.	Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.	J Natl Cancer Inst	97	6	433-8	2005
B20	Parker C, Muston D, Melia J, Moss S, Dearnaley D.	A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival.	Br J Cancer	94	10	1361-8	2006
B21	Makinen T, Tammela TL, Stenman UH, Maattanen L, Aro J, Juusela H, Martikainen P, Hakama M, Auvinen A.	Second round results of the Finnish population-based prostate cancer screening trial.	Clin Cancer Res	10	7	2231-6	2004

添付3-3 非採用文献リスト(C) 英文12+和文0=12文献

NO	Author	Title	Journal	Volu mes	Issu e	Page s	Year
C1	de Vries SH, Raaijmakers R, Kranse R, Blijenberg BG, Schröder FH.	Prostate cancer characteristics and prostate specific antigen changes in screening detected patients initially treated with a watchful waiting policy.	J Urol	172	6 Pt 1	2193- 6	2004
C2	van der Cruijssen-Koeter IW, Vis AN, Roobol MJ, Wildhagen MF, de Koning HJ, van der Kwast TH, Schröder FH	Comparison of screen detected and clinically diagnosed prostate cancer in the European Randomised study of Screening for Prostate Cancer, section Rotterdam	J Urol	174	1	121- 5	2005
C3	Roemeling S, Roobol MJ, Postma R, Gosselaar C, van der Kwast TH, Bangma CH, Schroder FH	Management and Survival of Screen-Detected Prostate Cancer Patients who Might Have Been Suitable for Active Surveillance	Eur Urol	50	3	475- 82	2006
C4	Rietbergen JWB, Boeken Kruger AE, Hoedemaeker RF, Bangma CH, Kirkels WJ, Schröder FH.	Repeat screening for prostate cancer after 1-year followup in 984 biopsied men: Clinical and pathological features of detected cancers.	J Urol	160	6 Pt 1	2121- 5	1998
C5	Vis AN, Boerma MO, Ciatto S, Hoedemaeker RF, Schröder FH, van der Kwast TH.	Detection of Prostate Cancer: A Comparative Study of the Diagnostic Efficacy of Sextant Transrectal versus Sextant Transperineal Biopsy.	Urol	56	4	617- 21	2000
C6	Gosselaar C, Roobol MJ, Roemeling S, de Vries SH, Cruijssen-Koeter I, van der Kwast TH, Schroder FH.	Screening for prostate cancer without digital rectal examination and transrectal ultrasound: results after four years in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam.	Prostate	66	6	625- 31	2006
C7	渡辺真, 斉藤雅人, 渡邊隼.	前立腺癌のスクリーニングにおける経直腸的超音波断層法の診断精度.	泌尿器科紀要	42	10	763- 6	1996
C8	Berger AP, Deibl M, Steiner H, Bektic J, Pelzer A, Spranger R, Klocker H, Bartsch G, Horninger W.	Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk.	Prostate	64	3	240- 5	2005
C9	Ciatto S, Gervasi G, Bonardi R, Frullini P, Zendron P, Lombardi C, Crocetti E, Zappa M.	Determining overdiagnosis by screening with DRE/TRUS or PSA (Florence pilot studies, 1991-1994).	Eur J Cancer	41	3	411- 5	2005
C10	Postma R, de Vries SH, Roobol MJ, Wildhagen MF, Schroder FH, van der Kwast TH.	Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years.	Cancer	103	4	708- 16	2005
C11	Brenner H, Arndt V.	Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis.	J Clin Oncol	23	3	441- 7	2005
C12	Roemeling S, Roobol MJ, Gosselaar C, Schroder FH.	Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).	Prostate	66	10	1076- 81	2006